Metabolic
Retatrutide 10mg
Buy Retatrutide 10mg in Australia — >99.6% HPLC tested with batch-specific COA. Same-day Australian dispatch.
Triple-receptor agonist research compound. GLP-1, GIP, and glucagon receptor activity. 39-amino acid synthetic peptide with C20 fatty diacid moiety.
Institutional pricing
Volume pricing applies automatically at checkout when commerce is live. For bulk institutional orders or custom quantities, contact pillarresearch@pm.me.
Retatrutide 10mg
Estimated launch price: $189 AUD
Add to cart is unavailable until launch. Enter your email and we'll notify you the moment Retatrutide 10mg is in stock.
No spam. Unsubscribe anytime. For research use only.
Researchers studying Retatrutide frequently study
Retatrutide Overview
Retatrutide is a 39-amino-acid synthetic peptide engineered as a unimolecular triple agonist of the GLP-1, GIP, and glucagon receptors. The molecule was constructed from a GIP peptide backbone with a C20 fatty diacid moiety attached to extend its circulating half-life to approximately six days. It represents the current frontier of incretin-class peptide research.
History
Retatrutide (developmental code LY3437943) was developed by Eli Lilly. Phase 2 and Phase 3 clinical programmes have been ongoing across multiple countries since 2022, building on a decade of GLP-1 / GIP dual agonist (Tirzepatide) research and extending the multi-receptor approach to include glucagon receptor activity.
Retatrutide Structure
Research Findings
Retatrutide has been investigated in incretin receptor pharmacology, body-composition models, and hepatic metabolism research. Published Phase 2 data report substantial body-weight reduction at the highest doses studied, alongside reduced hepatic fat content in liver substudies. Receptor binding studies confirm potent activity at all three target receptors.
Key Areas of Research:
- •Metabolic: GLP-1 / GIP / glucagon receptor activation
- •Body composition: Body-weight reduction in Phase 2 trials
- •Hepatic: Substantial liver-fat reduction in substudies
- •Energy expenditure: Glucagon-receptor-driven thermogenesis
The triple agonism profile distinguishes Retatrutide from earlier-generation single (Semaglutide) and dual (Tirzepatide) agonists. The addition of glucagon receptor activity introduces thermogenic and hepatic-metabolism components that extend the research utility of the molecule beyond purely incretin-driven outcomes.
Rosenstock J. et al. (2023). Retatrutide in adults with obesity — Phase 2 dose-finding study.
References
References are provided for research context. Pillar Research does not endorse or interpret published findings as therapeutic claims.
Retatrutide 10mg — research questions
Common questions for Australian researchers about Retatrutide 10mg.
What is Retatrutide?
Retatrutide is a 39-amino-acid synthetic peptide investigated as a triple agonist of the GLP-1, GIP, and glucagon receptors. It is supplied as an investigational research compound for in vitro laboratory research under the RUO framework.
How does Retatrutide differ from Semaglutide and Tirzepatide?
Semaglutide activates the GLP-1 receptor only. Tirzepatide activates GLP-1 and GIP. Retatrutide activates all three: GLP-1, GIP, and the glucagon receptor. The glucagon receptor activity is what distinguishes Retatrutide and is associated in published preclinical and Phase 2 work with increased thermogenesis and hepatic fatty acid oxidation.
What receptors does Retatrutide target?
Three G-protein coupled receptors: GLP-1, GIP, and the glucagon receptor. All three couple predominantly through the Gαs–cAMP–PKA pathway with tissue-specific downstream effects.
Is Retatrutide legal in Australia?
Retatrutide is classified as Schedule 4 (prescription-only) under the Australian Poisons Standard. It can be lawfully supplied for in vitro research purposes under the Research Use Only (RUO) framework. It is not listed on the Australian Register of Therapeutic Goods (ARTG) and is not a therapeutic good under the Therapeutic Goods Act 1989 (Cth).
What is the half-life of Retatrutide?
Approximately six days, supported by the C20 fatty diacid moiety which promotes albumin binding and resists DPP-4 degradation.
How is Retatrutide verified by Pillar Research?
Every batch is independently HPLC and mass spectrometry verified by a third-party Australian laboratory. The batch-specific Certificate of Analysis is downloadable from this page.
How should Retatrutide be stored?
Store lyophilised vials at 2–8 °C, protected from light and moisture, in the original sealed vial. After reconstitution, store at 2–8 °C for short-term use or −20 °C for longer storage. Avoid repeated freeze–thaw cycles.